Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients-Reference-Cited by-同舟云学术

Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients

Published:2021-10 Issue: Volume:142 Page:112076
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Yueying Chen,Jing Feng,Tian Yang,Yuqi Qiao,Jun Shen

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference48 articles.

1. The burden of inflammatory bowel disease in Europe in 2020;Zhao;J. Crohn’s Colitis,2021

2. Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases;Barnes;Gastroenterology,2021

3. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease;Hemperly;Clin. Pharmacokinet.,2018

4. Crohn’s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study;Ma;J. Crohn’s Colitis,2014

5. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab;Scaldaferri;PLoS One,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients;Heliyon;2023-04

2. Precision medicine and drug optimization in adult inflammatory bowel disease patients;Therapeutic Advances in Gastroenterology;2023-01

3. A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab;European Radiology;2022-07-20

4. Development and Validation of a Clinical Radiomics Nomogram to Predict Loss of Response in Crohn's Disease Patients Treated with Infliximab;SSRN Electronic Journal;2022